Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?
Video navigation menu
Clinical GLP-1RA trials with kidney outcomes or monitored kidney events 01:19
Which endpoint in the composite endpoint is driving outcomes? 05:19
Outcomes in subgroups of patients 07:23
Why may GLP-1RAs confer kidney benefit? 09:59
An ongoing kidney outcomes trial with GLP-1RA in CKD patients 12:00
Exploratory analyses suggest that treatment with ___ may result in ___ decline of eGFR in patients with eGFR <60 ml/min compared to all patients.
- A. liraglutide, but not semaglutide; more
- B. liraglutide, but not semaglutide; lesser
- C. liraglutide and semaglutide; similar
- D. liraglutide and semaglutide; lesser
Educational information
This lecture by Johannes Mann was part of the EBAC-accredited symposium "Cardiorenal cross-talk in diabetes: The preventive challenge in DKD for GLP-1RA" held during ERA EDTA Virtual Congress 2020.
Faculty
Johannes Mann, Department of Nephrology and Hypertension, Erlangen-Neurenberg, and KfH Kidney Center, Munich, Germany
Disclosures
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding
Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: